{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-003224","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.988039+00:00","generated_at":"2026-06-27T00:02:47.702272+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MeiraGTx reports 2021 net loss of $79.6M; cash $137.7M; pipeline advances","bullets":["Net loss $79.6M ($1.80/share) vs $58.0M ($1.54/share) in 2020; license revenue rose to $37.7M from $15.6M.","Cash and equivalents $137.7M at Dec 31, 2021; expects to fund operations through Q2 2023.","Phase 3 Lumeos trial for XLRP enrolling; received $30M milestone from Janssen.","Positive Phase 1 data for AAV-hAQP1 in xerostomia; Phase 2 start planned by end of 2022.","R&D expenses $67.1M vs $33.9M, driven by ophthalmology, neurology, and manufacturing programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-003224","json":"https://secwatch.observer/filing/0001558370-22-003224.json","markdown":"https://secwatch.observer/filing/0001558370-22-003224.md","text":"https://secwatch.observer/filing/0001558370-22-003224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837022003224/0001558370-22-003224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837022003224/mgtx-20220310x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:02:47.702272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}